Get the Stockscreener App
1.81
4.23%
-0.08
After Hours:
1.84
0.03
+1.66%
Casi Pharmaceuticals Inc stock is traded at $1.81, with a volume of 42,736.
It is down -4.23% in the last 24 hours and down -20.61% over the past month.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
See More
Previous Close:
$1.89
Open:
$1.74
24h Volume:
42,736
Relative Volume:
0.03
Market Cap:
$22.26M
Revenue:
$22.06M
Net Income/Loss:
$-30.94M
P/E Ratio:
-0.808
EPS:
-2.24
Net Cash Flow:
$-26.70M
1W Performance:
-2.69%
1M Performance:
-20.61%
6M Performance:
-13.71%
1Y Performance:
-68.90%
1-Day Range:
$1.74
$1.88
1-Week Range:
$1.74
$2.13
52-Week Range:
$1.0909
$6.50
Casi Pharmaceuticals Inc Stock (CASI) Company Profile
Name
Casi Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare CASI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CASI
Casi Pharmaceuticals Inc
|
1.81 | 29.28M | 22.06M | -30.94M | -26.70M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Casi Pharmaceuticals Inc Stock (CASI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Initiated | Mizuho | Buy |
| Oct-23-20 | Initiated | Oppenheimer | Outperform |
| Sep-22-16 | Initiated | Maxim Group | Buy |
| Oct-29-15 | Resumed | H.C. Wainwright | Buy |
| Jun-23-15 | Initiated | H.C. Wainwright | Buy |
View All
Casi Pharmaceuticals Inc Stock (CASI) Latest News
Reversal indicators forming on CASI Pharmaceuticals Inc. stockWeekly Profit Report & Fast Moving Stock Watchlists - newser.com
Will CASI Pharmaceuticals Inc. stock maintain dividend yieldJuly 2025 Sentiment & Accurate Buy Signal Notifications - newser.com
How sentiment analysis helps forecast CASI Pharmaceuticals Inc.Rate Cut & Safe Capital Growth Stock Tips - newser.com
Can CASI Pharmaceuticals Inc. stock attract ESG capital inflows2025 Geopolitical Influence & Real-Time Chart Pattern Alerts - newser.com
CASI Pharmaceuticals Inc. stock momentum explained2025 Risk Factors & Low Drawdown Momentum Ideas - newser.com
CASI Pharmaceuticals (NASDAQ:CASI) versus Neurocrine Biosciences (NASDAQ:NBIX) Critical Analysis - Defense World
Trend analysis for CASI Pharmaceuticals Inc. this weekRisk Management & Daily Growth Stock Tips - newser.com
Sector ETF performance correlation with CASI Pharmaceuticals Inc.2025 Analyst Calls & Safe Entry Point Identification - newser.com
Backtesting results for CASI Pharmaceuticals Inc. trading strategiesJuly 2025 Action & Stepwise Trade Signal Implementation - newser.com
Published on: 2025-10-09 04:50:23 - newser.com
Volume spikes in CASI Pharmaceuticals Inc. stock – what they meanJuly 2025 Setups & Low Risk Profit Maximizing Plans - newser.com
Can CASI Pharmaceuticals Inc. hit a new high this monthJuly 2025 PostEarnings & Weekly High Return Opportunities - newser.com
Head to Head Contrast: CASI Pharmaceuticals (NASDAQ:CASI) and Ardelyx (NASDAQ:ARDX) - Defense World
Evotec (NASDAQ:EVO) versus CASI Pharmaceuticals (NASDAQ:CASI) Critical Survey - Defense World
Does CASI Pharmaceuticals Inc. qualify in momentum factor screening2025 Analyst Calls & Growth Oriented Trading Recommendations - newser.com
Why CASI Pharmaceuticals Inc. stock remains undervaluedJuly 2025 Big Picture & High Return Stock Watch Alerts - newser.com
How to interpret RSI for CASI Pharmaceuticals Inc. stock2025 Key Highlights & Risk Controlled Stock Alerts - newser.com
Why CASI Pharmaceuticals Inc. is moving todayRate Hike & AI Powered Buy and Sell Recommendations - newser.com
Is CASI Pharmaceuticals Inc. showing signs of accumulation2025 Historical Comparison & Momentum Based Trading Signals - newser.com
Order flow analysis tools used on CASI Pharmaceuticals Inc.2025 EndofYear Setup & Safe Entry Zone Tips - newser.com
Casi Pharmaceuticals appoints James Hunag to board of directors - MSN
Will CASI Pharmaceuticals Inc. benefit from macro trendsJuly 2025 Outlook & Weekly High Return Stock Opportunities - newser.com
Intraday pattern recognizer results for CASI Pharmaceuticals Inc.2025 Market Sentiment & Fast Moving Trade Plans - newser.com
Little Excitement Around CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues As Shares Take 43% Pounding - Sahm
What analysts say about CASI Pharmaceuticals Inc stockHigh Beta Stocks & Small Investment Capital Tips - earlytimes.in
Casi Pharmaceuticals Inc Stock (CASI) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):